Abstract:The gene editing technology enables cutting or/and inserting the target gene precisely. The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) system relies on two major elements, a guide RNA (gRNA) that recognizes a specific DNA sequence, and a nuclease Cas9 that cuts the target DNA and creates double-strand breaks (DSBs). Among a few gene-editing technologies available, CRISPR/Cas9 system has showed tremendous advantages over the others, mainly due to high efficiency of Cas9 and simple design of gRNA. As a versatile and powerful tool for genome engineering, the CRISPR/Cas9 technology has been used to generate genetically modified mice with unprecedented simplicity and speed, simply by timed delivery of Cas9/gRNA ribonucleoproteins (RNPs) into pronuclear-stage zygotes. The modified protocol introduces Cas9 protein instead of Cas9 mRNA by rapid electroporation, which enables the gene editing occurring before the first replication of the mouse genome, thus generating non-mosaic mutant embryos. Furthermore, it could be used to produce multiple gene mutations in a single mouse by co-delivering several gRNAs targeted to different genes. Herein, we summarize current applications of CRISPR/Cas9 technology in the field of neuroscience, and aim to provide concise information and perspectives for better utilizing this technology. In brain research, the CRISPR/Cas9 system can be applied either at the one-cell stage of the fertilized eggs in the form of Cas9/gRNA ribonucleoproteins, or at the stage of embryos or adults in the form of plasmid DNA or the viral vectors (commonly AAV variants) respectively. To deliver the system specifically into the developmental or adult brain, in utero electroporation, or stereotaxic injection is commonly employed. Several reports show that AAV-assisted Cas9/gRNA system could achieve a satisfied efficiency for genome editing in the adult mouse brain, but results vary depending on Cas9 activity, gRNA design, detection methods, and the condition of endogenous DNA repair mechanisms. Remarkable efforts have also been made to enhance the incidence of homology-directed repair for precise gene modifications. Regarding therapeutic genome editing, a couple of recent in vivo studies demonstrate that CRISPR/Cas9 system could contract or remove disease-causing alleles in animal models of certain hereditary diseases such as retinitis pigmentosa and Huntington′s disease, raising hope for translating therapeutic genome editing to clinical patients. In addition, we discuss major challenges and critical improvements for this technology, including a few modifications for promoting precise editing in non-dividing cells in the case of adult brain. In the future, application of CRISPR/Cas9 technology would be enhanced greatly in neuroscience by developing cell type-specific, timed delivery system in vivo and by combining with other powerful techniques for dissecting brain neural circuits in health and disease.

Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Targeted RNA editing in brainstem alleviates respiratory dysfunction in a mouse model of Rett syndrome

Cell-Type-Specific Gene Inactivation and in Situ Restoration Via Recombinase-Based Flipping of Targeted Genomic Region

AAV-mediated FOXG1 gene editing in human Rett primary cells

A Prospective Treatment Option for Lysosomal Storage Diseases: CRISPR/Cas9 Gene Editing Technology for Mutation Correction in Induced Pluripotent Stem Cells

Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins

Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina

CRISPR/Cas9 genome editing clinical trials for neurodevelopmental disorders

Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy

Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies

Engineering self-deliverable ribonucleoproteins for genome editing in the brain

Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing

A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE

Clinical-grade intranasal NGF fuels neurological and metabolic functions of Mecp2 -deficient mice

The Efficacy of a Human-Ready mini MECP2 Gene Therapy in a Pre-Clinical Model of Rett Syndrome

Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells

Allele-Specific Gene Editing Rescues Pathology in a Human Model of Charcot-Marie-Tooth Disease Type 2E

Strategy for Applying CRISPR/Cas9 Gene Editing Technology in Neuroscience